当前位置: X-MOL 学术Sens. Actuators B Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A sample-to-answer quantitative platform for point-of-care testing of biochemical markers in whole blood
Sensors and Actuators B: Chemical ( IF 8.0 ) Pub Date : 2020-01-20 , DOI: 10.1016/j.snb.2020.127750
Huan Xu , Anyue Xia , Jie Luo , Mingxuan Gao , Renkuan Liao , Fake Li , Qiu Zhong , Wenqing Zhang , Yang Wang , Jinhui Cui , Weiling Fu , Kai Chang , Mingzhe Gan , Wenbin Jiang , Ming Chen

Point-of-care quantitative detection of biochemical markers has broad applications in resource-limited settings. However, current challenges including difficulty in sample preparation and limitation in result quantitation make point-of-care detection platforms failed to achieve fully sample-to-answer detection or meet the clinical quantitative demands. Here, we developed a novel point-of-care platform to realize fully sample-to-answer biochemical marker quantitation in whole blood. Our platform integrated a plasma separation module and a detection module. The plasma separation module contained a plasma separation strip could rapidly separate the plasma from whole blood samples by lateral flow. The detection module generated a colorimetric signal which could be quantified by the smartphone ambient light sensor (ALS) in an equipment-free manner. As a proof-of-concept, two hepatobiliary disease-associated markers, total bilirubin (TBil) and direct bilirubin (DBil), were detected from whole blood to quantitative result. The quantitative performance for clinical samples was highly consistent with the well-established clinical chemistry analyzer. Our platform exhibited remarkable advantages of significant portability (< 40 g), low cost (< $5), rapidity (< 5 min), instrument-free, high sensitivity (< 1 μM), and accuracy (89.5 % for TBil, 94.7 % for DBil), which showed up a great potential for biochemical markers detection in resource-limited settings.



中文翻译:

用于全血中生化标志物即时检验的从样品到答案的定量平台

现场即时检测生化标记物在资源有限的环境中具有广泛的应用。但是,当前的挑战包括样品制备的困难和结果定量的局限性,使得即时检测点检测平台无法完全实现从样品到答案的检测或满足临床定量需求。在这里,我们开发了一种新颖的即时护理平台,以实现全血中从样品到答案的生化标记物的完全定量。我们的平台集成了血浆分离模块和检测模块。血浆分离模块包含血浆分离条,可通过侧向流动将血浆与全血样品快速分离。检测模块生成比色信号,该比色信号可以由智能手机环境光传感器(ALS)以无设备方式量化。作为概念验证,从全血中检测到两种与肝胆疾病相关的标志物总胆红素(TBil)和直接胆红素(DBil)。临床样品的定量性能与完善的临床化学分析仪高度一致。我们的平台展现出显着的优势,具有可移植性(<40 g),低成本(<$ 5),快速(<5 min),无需仪器,高灵敏度(<1μM)和准确性(TBil为89.5%,94.7% DBil),在资源有限的环境中显示出生化标记检测的巨大潜力。临床样品的定量性能与完善的临床化学分析仪高度一致。我们的平台展现出显着的优势,具有可移植性(<40 g),低成本(<$ 5),快速(<5 min),无需仪器,高灵敏度(<1μM)和准确性(TBil为89.5%,94.7% (DBil),在资源有限的环境中显示出生化标记检测的巨大潜力。临床样品的定量性能与完善的临床化学分析仪高度一致。我们的平台展现出显着的优势,具有可移植性(<40 g),低成本(<$ 5),快速(<5 min),无需仪器,高灵敏度(<1μM)和准确性(TBil为89.5%,94.7% DBil),在资源有限的环境中显示出生化标记检测的巨大潜力。

更新日期:2020-01-21
down
wechat
bug